Bruce D. Neviaser
Directeur/Membre du Conseil chez EraGen Biosciences, Inc.
Profil
Bruce D.
Neviaser is the founder of Continuum Investment LP, which was founded in 2005.
He held the title of General Partner from 2005 to 2023.
He is currently the Director at EraGen Biosciences, Inc. since 2005.
Mr. Neviaser has also held positions as Chairman at Great Wolf Resorts Holdings, Inc., Director at Universal Food & Beverage Co., Director at Cellectar, Inc., and Advisor at Phenomenelle Angels LLC.
He obtained his undergraduate degree from the University of Wisconsin.
Postes actifs de Bruce D. Neviaser
| Sociétés | Poste | Début |
|---|---|---|
EraGen Biosciences, Inc.
 EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI. | Directeur/Membre du Conseil | 01/01/2005 |
Anciens postes connus de Bruce D. Neviaser
| Sociétés | Poste | Fin |
|---|---|---|
Continuum Investment LP
 Continuum Investment LP Investment ManagersFinance Continuum Investment LP (Continuum Investment) is a venture capital firm founded in 2005 by Bruce D Neviaser. The firm is headquartered in Middleton, Wisconsin. | Fondateur | 31/12/2023 |
Cellectar, Inc.
 Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Directeur/Membre du Conseil | 01/04/2011 |
Phenomenelle Angels LLC
 Phenomenelle Angels LLC Investment ManagersFinance Phenomenelle Angels LLC (Phenomenelle Angels) is a venture capital firm founded in 2006 by Lauren A. Flanagan and Joe P. Hildebrandt. The firm is headquartered in Madison, Wisconsin. | Corporate Officer/Principal | 31/12/2009 |
Great Wolf Resorts Holdings, Inc.
 Great Wolf Resorts Holdings, Inc. Hotels/Resorts/Cruise linesConsumer Services Great Wolf Resorts Holdings, Inc. owns and operates indoor water parks and resorts. The firm offers arcade and game rooms, fitness rooms, themed restaurants, spas, supervised children's activities, and other amenities. The company was founded in 1997 and is headquartered in Chicago, IL. | Président | 11/09/2006 |
Universal Food & Beverage Co.
 Universal Food & Beverage Co. Food DistributorsDistribution Services Universal Food & Beverage Co. produces and wholesales food and beverage products. The company was founded in 2004 and is headquartered in St. Charles, IL. | Directeur/Membre du Conseil | - |
Formation de Bruce D. Neviaser
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Great Wolf Resorts Holdings, Inc.
Great Wolf Resorts Holdings, Inc. Hotels/Resorts/Cruise linesConsumer Services Great Wolf Resorts Holdings, Inc. owns and operates indoor water parks and resorts. The firm offers arcade and game rooms, fitness rooms, themed restaurants, spas, supervised children's activities, and other amenities. The company was founded in 1997 and is headquartered in Chicago, IL. | Consumer Services |
EraGen Biosciences, Inc.
EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI. | Health Technology |
Universal Food & Beverage Co.
Universal Food & Beverage Co. Food DistributorsDistribution Services Universal Food & Beverage Co. produces and wholesales food and beverage products. The company was founded in 2004 and is headquartered in St. Charles, IL. | Distribution Services |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Commercial Services |
Phenomenelle Angels LLC
Phenomenelle Angels LLC Investment ManagersFinance Phenomenelle Angels LLC (Phenomenelle Angels) is a venture capital firm founded in 2006 by Lauren A. Flanagan and Joe P. Hildebrandt. The firm is headquartered in Madison, Wisconsin. | Finance |
Continuum Investment LP
Continuum Investment LP Investment ManagersFinance Continuum Investment LP (Continuum Investment) is a venture capital firm founded in 2005 by Bruce D Neviaser. The firm is headquartered in Middleton, Wisconsin. | Finance |
